prikaz prve stranice dokumenta Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives
Embargo period 2025-06-01
Scientific paper - Review paper
Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives
Annals of Hematology, 103 (2023), 5; 1513-1523. https://doi.org/10.1007/s00277-023-05426-9
Krečak, Ivan; Verstovsek, Srdan; Lucijanić, Marko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Krečak, I., Verstovsek, S. & Lucijanić, M. (2023). Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives. Annals of Hematology, 103. (5), 1513-1523. doi: 10.1007/s00277-023-05426-9

Krečak, Ivan, et al. "Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives." Annals of Hematology, vol. 103, no. 5, 2023, pp. 1513-1523. https://doi.org/10.1007/s00277-023-05426-9

Krečak, Ivan, Srdan Verstovsek and Marko Lucijanić. "Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives." Annals of Hematology 103, no. 5 (2023): 1513-1523. https://doi.org/10.1007/s00277-023-05426-9

Krečak, I., Verstovsek, S. and Lucijanić, M. (2023) 'Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives', Annals of Hematology, 103(5), pp. 1513-1523. doi: 10.1007/s00277-023-05426-9

Krečak I, Verstovsek S, Lucijanić M. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives. Annals of Hematology [Internet]. 2023 September 04 [cited 2024 July 06];103(5):1513-1523. doi: 10.1007/s00277-023-05426-9

I. Krečak, S. Verstovsek and M. Lucijanić, "Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives", Annals of Hematology, vol. 103, no. 5, pp. 1513-1523, September 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:613579. [Accessed: 06 July 2024]

Metadata
Title (english)Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives
AuthorIvan Krečak
AuthorSrdan Verstovsek
AuthorMarko Lucijanić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
The exact prognostic role of cardiovascular (CV) risk factors in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms (MPNs) remains unknown as it is often masked by other MPN-related features that bear strong prognostic impact on thrombotic risk. Therefore, current MPN treatment is not primarily guided by presence of CV risk factors. Treatment of CV risk factors in MPN patients usually mirrors that from the general population, despite the fact that CV risk factors in MPNs have their own specificities. Moreover, the optimal target levels for different metabolic deflections in MPNs (i.e., low-density lipoprotein, serum uric acid, or glycated hemoglobin levels) have not been defined. In the current review, we separately discuss the most important aspects of every individual CV risk factor (arterial hypertension, hyperlipidemia, chronic kidney disease, smoking, diabetes mellitus, hyperuricemia, and obesity and cachexia) in MPNs, summarize recent advances in the field, and propose future directions and research areas which may be needed to appropriately manage CV risk factors in MPNs.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleAnnals of Hematology
Numberingvol. 103, no. 5, pp. 1513-1523
p-ISSN0939-5555
e-ISSN1432-0584
DOIhttps://doi.org/10.1007/s00277-023-05426-9
URN:NBNurn:nbn:hr:105:613579
Publication2023-09-04
Document URLhttps://link.springer.com/10.1007/s00277-023-05426-9
Type of resourceText
Access conditionsEmbargoed access
Embargo expiration date: 2025-06-01
Terms of useLicence In copyright icon
Created on2024-05-06 08:16:50